Christopher Benecchi - Aug 5, 2024 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Business Officer
Signature
Brandon Marsh, attorney in fact for Christopher Benecchi
Stock symbol
SAGE
Transactions as of
Aug 5, 2024
Transactions value $
-$42,605
Form type
4
Date filed
8/7/2024, 04:04 PM
Previous filing
Feb 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +16.2K +230.05% $0.00 23.2K Aug 5, 2024 Direct F1, F2
transaction SAGE Common Stock Tax liability -$42.6K -4.76K -20.46% $8.96 18.5K Aug 5, 2024 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 13, 2024, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 40,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on August 5, 2024, resulting in the vesting of the PSUs as to 16,200 shares.
F2 Reflects beneficial ownership balance which includes 1,112 shares purchased on June 28, 2024 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.